B-Cell Non-Hodgkin's Lymphoma: Epidemiology Forecast to 2027

2019-06-25
Price :
Published : Jun-2019
No. of Pages : 44
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 B-Cell NHL: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for B-Cell NHL (2017-2027)
3.5.1 Diagnosed Incident Cases of B-Cell NHL
3.5.2 Age-Specific Diagnosed Incident Cases of B-Cell NHL
3.5.3 Sex-Specific Diagnosed Incident Cases of B-Cell NHL
3.5.4 Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
3.5.5 Diagnosed Incident Cases of DLBCL by Cancer Staging
3.5.6 Diagnosed Incident Cases of FL by Cancer Staging
3.5.7 Diagnosed Incident Cases of MZL by Cancer Staging
3.5.8 Diagnosed Incident Cases of MCL by Cancer Staging
3.5.9 Diagnosed Incident Cases of FL by Grade
3.5.10 Diagnosed Prevalent Cases of B-Cell NHL
3.5.11 Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

1.1 List of Tables
Table 1: B-Cell NHL Cancer Stages
Table 2: Risk Factors and Comorbidities for NHL

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of B-Cell NHL, Both Sexes, Ages ?18 Years, 2017 and 2027
Figure 2: 7MM, Age-Standardized Diagnosed Incidence of B-Cell NHL, Ages ?18 Years, 2017
Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of B-Cell NHL, Ages ?18 Years, 2017
Figure 4: Sources Used for Diagnosed Incident Cases of B-Cell NHL
Figure 5: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
Figure 6: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL by Cancer Staging
Figure 7: Sources Used for Diagnosed Incident Cases of FL by Grade
Figure 8: Sources Used for Diagnosed Prevalent Cases of B-Cell NHL
Figure 9: Sources Used for Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
Figure 10: 7MM, Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ?18 Years, 2017
Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, 2017
Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ?18 Years, 2017
Figure 13: 7MM, Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ?18 Years, 2017
Figure 14: 7MM, Diagnosed Incident Cases of DLBCL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 15: 7MM, Diagnosed Incident Cases of FL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 16: 7MM, Diagnosed Incident Cases of MZL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 17: 7MM, Diagnosed Incident Cases of MCL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 18: 7MM, Diagnosed Incident Cases of FL by Grade, Men and Women, Ages ?18 Years, 2017
Figure 19: 7MM, Diagnosed Prevalent Cases of B-Cell NHL, Men and Women, ?18 Years, 2017
Figure 20: 7MM, Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ?18 Years, 2017
Filed in: Pharmaceutical
Publisher : GlobalData